

Research Journal Publications—Published in 2013

1. Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM, Yock TI, Tarbell NJ, Shih HA, Loeffler JS, and Oh KS, **Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.** *J Neurooncol*, 2013. 115(3): p. 411-9.
2. Allan BJ, Parikh PP, Diaz S, Perez EA, Neville HL, and Sola JE, **Predictors of survival and incidence of hepatoblastoma in the paediatric population.** *HPB (Oxford)*, 2013. 15(10): p. 741-6.
3. Arem H, Reedy J, Sampson J, Jiao L, Hollenbeck AR, Risch H, Mayne ST, and Stolzenberg-Solomon RZ, **The Healthy Eating Index 2005 and risk for pancreatic cancer in the NIH-AARP study.** *J Natl Cancer Inst*, 2013. 105(17): p. 1298-305.
4. Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, and Cormier JN, **Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States.** *J Pediatr Surg*, 2013. 48(11): p. 2207-13.
5. Bagley JH, Babu R, Friedman AH, and Adamson C, **Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas.** *Neurosurg Focus*, 2013. 34(2): p. E7.
6. Bekelman JE, Handorf EA, Guzzo T, Evan Pollack C, Christodouleas J, Resnick MJ, Swisher-McClure S, Vaughn D, Ten Have T, Polsky D, and Mitra N, **Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research.** *Value Health*, 2013. 16(4): p. 610-8.
7. Bikov KA, Mullins CD, Seal B, Onukwugha E, and Hanna N, **Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare.** *Med Care*, 2013.
8. Bosire C, Stampfer MJ, Subar AF, Park Y, Kirkpatrick SI, Chiuve SE, Hollenbeck AR, and Reedy J, **Index-based dietary patterns and the risk of prostate cancer in the NIH-AARP diet and health study.** *Am J Epidemiol*, 2013. 177(6): p. 504-13.
9. Bosire C, Stampfer MJ, Subar AF, Wilson KM, Park Y, and Sinha R, **Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study.** *Cancer Causes Control*, 2013. 24(8): p. 1527-34.
10. Brawarsky P, Neville BA, Fitzmaurice GM, Earle C, and Haas JS, **Surveillance after resection for colorectal cancer.** *Cancer*, 2013. 119(6): p. 1235-42.
11. Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, and Daniel Mullins C, **Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival.** *Value Health*, 2013. 16(5): p. 760-8.

12. Chakraborty S and Singh S, **Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study.** *Ann Gastroenterol*, 2013. 26(4): p. 346-352.
13. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, and Giordano SH, **Trastuzumab-related cardiotoxicity among older patients with breast cancer.** *J Clin Oncol*, 2013. 31(33): p. 4222-8.
14. Cook MB, Matthews CE, Gunja MZ, Abid Z, Freedman ND, and Abnet CC, **Physical activity and sedentary behavior in relation to esophageal and gastric cancers in the NIH-AARP cohort.** *PLoS One*, 2013. 8(12): p. e84805.
15. Cooper GS, Kou TD, and Rex DK, **Complications following colonoscopy with anesthesia assistance: a population-based analysis.** *JAMA Intern Med*, 2013. 173(7): p. 551-6.
16. Corcoran AT, Smaldone MC, Egleston BL, Simhan J, Ginzburg S, Morgan TM, Walton J, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, and Kutikov A, **Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.** *BJU Int*, 2013. 112(2): p. 161-8.
17. Daniel CR, Park Y, Chow WH, Graubard BI, Hollenbeck AR, and Sinha R, **Intake of fiber and fiber-rich plant foods is associated with a lower risk of renal cell carcinoma in a large US cohort.** *Am J Clin Nutr*, 2013. 97(5): p. 1036-43.
18. Daugherty SE, Lacey JV, Jr., Pfeiffer RM, Park Y, Hoover RN, and Silverman DT, **Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study.** *Int J Cancer*, 2013. 133(2): p. 462-72.
19. Dellavalle CT, Daniel CR, Aschebrook-Kilfoy B, Hollenbeck AR, Cross AJ, Sinha R, and Ward MH, **Dietary intake of nitrate and nitrite and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study.** *Br J Cancer*, 2013. 108(1): p. 205-12.
20. DeSantis C, Naishadham D, and Jemal A, **Cancer statistics for African Americans, 2013.** *CA: A Cancer Journal for Clinicians*, 2013. 63(3): p. 151-166.
21. Dodgion CM, Neville BA, Lipsitz SR, Hu YY, Schrag D, Breen E, and Greenberg CC, **Do older Americans undergo stoma reversal following low anterior resection for rectal cancer?** *J Surg Res*, 2013. 183(1): p. 238-45.
22. Drahos J, Wu M, Anderson WF, Trivers KF, King J, Rosenberg PS, Ehemann C, and Cook MB, **Regional variations in esophageal cancer rates by census region in the United States, 1999-2008.** *PLoS One*, 2013. 8(7): p. e67913.
23. Duong LA and Richardson LC, **Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008.** *J Registry Manag*, 2013. 40(2): p. 59-64.

24. Elliott P, Shaddick G, Douglass M, de Hoogh K, Briggs DJ, and Toledano MB, **Adult cancers near high-voltage overhead power lines.** *Epidemiology*, 2013. 24(2): p. 184-90.
25. Enyioha C, Roman SA, and Sosa JA, **Central lymph node dissection in patients with papillary thyroid cancer: a population level analysis of 14,257 cases.** *Am J Surg*, 2013. 205(6): p. 655-61.
26. Faje AT, Nachtigall L, Wexler D, Miller KK, Klibanski A, and Makimura H, **Central diabetes insipidus: a previously unreported side effect of temozolomide.** *J Clin Endocrinol Metab*, 2013. 98(10): p. 3926-31.
27. Fedewa SA and Jemal A, **Prostate cancer disease severity and country of origin among black men in the United States.** *Prostate Cancer Prostatic Dis*, 2013. 16(2): p. 176-80.
28. Fitzgerald TL, Zervos E, and Wong JH, **Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer.** *J Cancer Epidemiol*, 2013. 2013: p. 408460.
29. Franko J, Hucec V, Lopes TL, and Goldman CD, **Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm.** *Ann Surg Oncol*, 2013. 20(2): p. 357-61.
30. Freedman ND, Derakhshan MH, Abnet CC, Schatzkin A, Hollenbeck AR, and McColl KE, **Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women.** *Eur J Cancer*, 2010. 46(13): p. 2473-8.
31. Fung C, Fossa SD, Milano MT, Oldenburg J, and Travis LB, **Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.** *J Clin Oncol*, 2013. 31(30): p. 3807-14.
32. Gardner TB, Glass LM, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Tsapakos MJ, Suriawinata AA, Tsongalis GJ, Pipas JM, and Gordon SR, **Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults.** *Am J Gastroenterol*, 2013. 108(10): p. 1546-50.
33. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, Hershman DL, and Wright JD, **Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.** *Gynecol Oncol*, 2013. 131(1): p. 42-5.
34. Ghia AJ, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, and Brown PD, **Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis.** *Neurosurgery*, 2013. 72(2): p. 203-9.
35. Gleason MX, Mdzinarishvili T, Are C, Sasson A, Sherman A, Shats O, and Sherman S, **Prognostic estimator of survival for patients with localized and extended pancreatic ductal adenocarcinoma.** *Cancer Inform*, 2013. 12: p. 103-14.
36. Groeschl RT, Clark Gamblin T, and Turaga KK, **Surgical resection in hepatocellular carcinoma patients with minimal background fibrosis: a strategy in the era of organ shortage.** *Ann Surg Oncol*, 2013. 20(6): p. 2043-8.

37. Groeschl RT, Gamblin TC, and Turaga KK, **Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint.** *Ann Surg Oncol*, 2013. 20(11): p. 3591-5.
38. Handorf EA, Bekelman JE, Heitjan DF, and Mitra N, **EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.** *Ann Appl Stat*, 2013. 7(4): p. 2062-2080.
39. Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, and Neugut AI, **Contraindicated use of bevacizumab and toxicity in elderly patients with cancer.** *J Clin Oncol*, 2013. 31(28): p. 3592-9.
40. Hofmann JN, Moore SC, Lim U, Park Y, Baris D, Hollenbeck AR, Matthews CE, Gibson TM, Hartge P, and Purdue MP, **Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study.** *Am J Epidemiol*, 2013. 177(8): p. 776-86.
41. Hou N and Huo D, **A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase.** *Breast Cancer Res Treat*, 2013. 138(2): p. 633-41.
42. Hsieh MC, Wu XC, Andrews PA, and Chen VW, **Racial and Ethnic Disparities in the Incidence and Trends of Soft Tissue Sarcoma Among Adolescents and Young Adults in the United States, 1995-2008.** *J Adolesc Young Adult Oncol*, 2013. 2(3): p. 89-94.
43. Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JF, Kamel IR, and Pawlik TM, **Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma.** *J Gastrointest Surg*, 2013. 17(10): p. 1774-83.
44. Jacobs BL, Zhang Y, Tan HJ, Ye Z, Skolarus TA, and Hollenbeck BK, **Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms.** *J Urol*, 2013. 189(1): p. 59-65.
45. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Ehemann C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, and Edwards BK, **Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.** *J Natl Cancer Inst*, 2013. 105(3): p. 175-201.
46. Jinkins LJ, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, and Riall TS, **Current trends in preoperative biliary stenting in patients with pancreatic cancer.** *Surgery*, 2013. 154(2): p. 179-89.
47. Johnson DR, Leeper HE, and Uhm JH, **Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.** *Cancer*, 2013. 119(19): p. 3489-95.
48. Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hollenbeck AR, and Rohan TE, **Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(5): p. 848-54.

49. Kaplan HG, Malmgren JA, Li CI, and Calip GS, **Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.** *Breast Cancer Res Treat*, 2013. 142(3): p. 629-36.
50. Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL, 3rd, Hofmann JN, Chow WH, and Purdue MP, **Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010.** *Am J Epidemiol*, 2013. 177(12): p. 1368-77.
51. Kirschner AN, Kidd EA, Dewees T, and Perkins SM, **Treatment approach and outcomes of vaginal melanoma.** *Int J Gynecol Cancer*, 2013. 23(8): p. 1484-9.
52. Kuo EJ, Goffredo P, Sosa JA, and Roman SA, **Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis.** *Thyroid*, 2013. 23(10): p. 1305-11.
53. Lai GY, Park Y, Hartge P, Hollenbeck AR, and Freedman ND, **The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study.** *J Clin Endocrinol Metab*, 2013. 98(3): p. E497-502.
54. Lam TK, Moore SC, Brinton LA, Smith L, Hollenbeck AR, Gierach GL, and Freedman ND, **Anthropometric measures and physical activity and the risk of lung cancer in never-smokers: a prospective cohort study.** *PLoS One*, 2013. 8(8): p. e70672.
55. Lang JE, Summers DE, Cui H, Carey JN, Viscusi RK, Hurst CA, Waer AL, Ley ML, Sener SF, and Vijayasekaran A, **Trends in post-mastectomy reconstruction: a SEER database analysis.** *J Surg Oncol*, 2013. 108(3): p. 163-8.
56. Lin SW, Wheeler DC, Park Y, Spriggs M, Hollenbeck AR, Freedman DM, and Abnet CC, **Prospective study of ultraviolet radiation exposure and mortality risk in the United States.** *Am J Epidemiol*, 2013. 178(4): p. 521-33.
57. Liu P, Li X, Mittendorf EA, Li J, Du XL, He J, Ren Y, Yang J, Hunt KK, and Yi M, **Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer.** *Br J Cancer*, 2013. 109(5): p. 1302-9.
58. Luu C, Goldstein L, Goldner B, Schoellhammer HF, and Chen SL, **Trends in radiotherapy after breast-conserving surgery in elderly patients with early-stage breast cancer.** *Ann Surg Oncol*, 2013. 20(10): p. 3266-73.
59. Mandal R, Bolt DM, and Shah BK, **Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US.** *Acta Oncol*, 2013. 52(4): p. 837-41.
60. McCarthy BJ, Kruchko C, and Dolecek TA, **The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260) on non-malignant brain and central nervous system tumor incidence trends.** *J Registry Manag*, 2013. 40(1): p. 32-5.

61. Miller PE, Cross AJ, Subar AF, Krebs-Smith SM, Park Y, Powell-Wiley T, Hollenbeck A, and Reedy J, **Comparison of 4 established DASH diet indexes: examining associations of index scores and colorectal cancer.** *Am J Clin Nutr*, 2013. 98(3): p. 794-803.
62. Miura JT, Evans DB, Pappas SG, Gamblin TC, and Turaga KK, **Borderline resectable/locally advanced pancreatic adenocarcinoma: improvements needed in population-based registries.** *Ann Surg Oncol*, 2013. 20(13): p. 4338-47.
63. Mocellin S and Nitti D, **Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531).** *Ann Oncol*, 2013. 24(12): p. 3040-4.
64. Moten A, Obirizeze A, and Wilson LL, **Characterizing lobular carcinoma of the male breast using the SEER database.** *J Surg Res*, 2013. 185(2): p. e71-6.
65. Mukherjee D, Chaichana KL, Parker SL, Gokaslan ZL, and McGirt MJ, **Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database.** *Eur Spine J*, 2013. 22(6): p. 1375-82.
66. Nelson RA, Vogelzang N, and Pal SK, **A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.** *Clin Genitourin Cancer*, 2013. 11(3): p. 303-10.
67. Neuman HB, O'Connor ES, Weiss J, Loconte NK, Greenblatt DY, Greenberg CC, and Smith MA, **Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database.** *Cancer*, 2013. 119(3): p. 639-47.
68. Ng VY, Scharschmidt TJ, Mayerson JL, and Fisher JL, **Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions.** *Anticancer Res*, 2013. 33(6): p. 2597-604.
69. Nguyen XV, Choudhury KR, Eastwood JD, Lyman GH, Esclamado RM, Werner JD, and Hoang JK, **Incidental thyroid nodules on CT: evaluation of 2 risk-categorization methods for work-up of nodules.** *AJNR Am J Neuroradiol*, 2013. 34(9): p. 1812-7.
70. Nyante SJ, Dallal CM, Gierach GL, Park Y, Hollenbeck AR, and Brinton LA, **Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study.** *Am J Epidemiol*, 2013. 178(3): p. 359-71.
71. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, and Barnholtz-Sloan JS, **CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.** *Neuro Oncol*, 2013. 15 Suppl 2: p. ii1-56.
72. Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, and Khuri FR, **Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.** *Oncologist*, 2013. 18(5): p. 600-10.
73. Pal SK, Nelson RA, and Vogelzang N, **Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.** *PLoS One*, 2013. 8(5): p. e63341.

74. Pelsler C, Mondul AM, Hollenbeck AR, and Park Y, **Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(4): p. 697-707.
75. Perkins SM, Fei W, Mitra N, and Shinohara ET, **Late causes of death in children treated for CNS malignancies.** *J Neurooncol*, 2013. 115(1): p. 79-85.
76. Pfeiffer RM, Park Y, Kreimer AR, Lacey JV, Jr., Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, and Hartge P, **Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies.** *PLoS Med*, 2013. 10(7): p. e1001492.
77. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner B, Webb PM, Cramer DW, Wentzensen N, Terry KL, and Tworoger SS, **Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(3): p. 429-37.
78. Prasad SM, Gu X, Kowalczyk KJ, Lipsitz SR, Nguyen PL, and Hu JC, **Morbidity and costs of salvage vs. primary radical prostatectomy in older men.** *Urol Oncol*, 2013. 31(8): p. 1477-82.
79. Rauh-Hain JA, Davis M, Clemmer J, Clark RM, Growdon WB, Goodman AK, Boruta DM, 2nd, Schorge JO, and del Carmen MG, **Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.** *Gynecol Oncol*, 2013. 131(2): p. 404-9.
80. Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman AK, Boruta DM, 2nd, Schorge JO, and del Carmen MG, **Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.** *Gynecol Oncol*, 2013. 131(1): p. 46-51.
81. Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, and Hornbrook MC, **Validation of electronic data on chemotherapy and hormone therapy use in HMOs.** *Med Care*, 2013. 51(10): p. e67-73.
82. Roetzheim RG, Lee JH, Ferrante JM, Gonzalez EC, Chen R, Fisher KJ, Love-Jackson K, and McCarthy EP, **The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries.** *J Am Board Fam Med*, 2013. 26(6): p. 637-47.
83. Ruiz M, Reske T, Cefalu C, and Estrada J, **Differences in outcomes between elderly and nonelderly breast cancer patients in Louisiana.** *Am J Med Sci*, 2013. 346(5): p. 377-80.
84. Schneider DF, Chen H, and Sippel RS, **Impact of lymph node ratio on survival in papillary thyroid cancer.** *Ann Surg Oncol*, 2013. 20(6): p. 1906-11.
85. Schneider EB, Haider AH, Hyder O, Efron JE, Lidor AO, and Pawlik TM, **Assessing short- and long-term outcomes among black vs white Medicare patients undergoing resection of colorectal cancer.** *Am J Surg*, 2013. 205(4): p. 402-8.

86. Schreiber D, Chen SC, Rineer J, Weiss J, Rotman M, and Schwartz D, **Racial and socioeconomic disparities in the selection of prostate brachytherapy.** *J Contemp Brachytherapy*, 2013. 5(3): p. 139-43.
87. Shao YH, Moore DF, Shih W, Lin Y, Jang TL, and Lu-Yao GL, **Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.** *BJU Int*, 2013. 111(5): p. 745-52.
88. Sharma C, Deutsch I, Herzog TJ, Lu YS, Neugut AI, Lewin SN, Chao CK, Hershman DL, and Wright JD, **Patterns of care for locally advanced vulvar cancer.** *Am J Obstet Gynecol*, 2013. 209(1): p. 60.e1-5.
89. Sheets NC, Hendrix LH, Allen IM, and Chen RC, **Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis.** *Cancer*, 2013. 119(18): p. 3295-301.
90. Showalter SL, Grover S, Sharma S, Lin L, and Czerniecki BJ, **Factors influencing surgical and adjuvant therapy in stage I breast cancer: a SEER 18 database analysis.** *Ann Surg Oncol*, 2013. 20(4): p. 1287-94.
91. Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, and Meredith KL, **Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis.** *Cancer*, 2013. 119(9): p. 1636-42.
92. Siegel R, Naishadham D, and Jemal A, **Cancer statistics, 2013.** *CA: A Cancer Journal for Clinicians*, 2013. 63(1): p. 11-30.
93. Siegel RL, Devesa SS, Cokkinides V, Ma J, and Jemal A, **State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(1): p. 25-31.
94. Smith JK, Ng SC, Zhou Z, Carroll JE, McDade TP, Shah SA, and Tseng JF, **Does increasing insurance improve outcomes for US cancer patients?** *J Surg Res*, 2013. 185(1): p. 15-20.
95. Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G, Hopenhayn C, Cozen W, Saber MS, Huang Y, Peters ES, Lynch CF, Wilkinson EJ, Rajeevan MS, Lyu C, and Saraiya M, **Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction.** *J Low Genit Tract Dis*, 2013. 17(4): p. 397-403.
96. Stolzenberg-Solomon RZ, Schairer C, Moore S, Hollenbeck A, and Silverman DT, **Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort.** *Am J Clin Nutr*, 2013. 98(4): p. 1057-65.
97. Strobe SA, Chang SH, Chen L, Sandhu G, Piccirillo JF, and Schootman M, **Survival impact of followup care after radical cystectomy for bladder cancer.** *J Urol*, 2013. 190(5): p. 1698-703.

98. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, and Brinton LA, **Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?** *Int J Cancer*, 2013. 132(2): p. 417-26.
99. Tyson MD, Humphreys MR, Parker AS, Thiel DD, Joseph RW, Andrews PE, and Castle EP, **Age-period-cohort analysis of renal cell carcinoma in United States adults.** *Urology*, 2013. 82(1): p. 43-7.
100. Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, and Gross CP, **Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.** *Chest*, 2013. 143(2): p. 429-35.
101. Wagner AE, Pappas L, Ghia AJ, and Gaffney DK, **Impact of tumor size on survival in cancer of the cervix and validation of stage IIA1 and IIA2 subdivisions.** *Gynecol Oncol*, 2013. 129(3): p. 517-21.
102. Walker GV, Giordano SH, Williams M, Jiang J, Niu J, MacKinnon J, Anderson P, Wohler B, Sinclair AH, Boscoe FP, Schymura MJ, Buchholz TA, and Smith BD, **Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries.** *Int J Radiat Oncol Biol Phys*, 2013. 86(4): p. 686-93.
103. Warren JL, Harlan LC, Stevens J, Little RF, and Abel GA, **Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.** *J Clin Oncol*, 2013. 31(16): p. 1984-9.
104. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, and McGlynn KA, **Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States.** *Am J Gastroenterol*, 2013. 108(8): p. 1314-21.
105. Wirtz HS, Buist DS, Galow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, and Boudreau DM, **Frequent antibiotic use and second breast cancer events.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(9): p. 1588-99.
106. Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, Gloor B, and Koeberle D, **Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008.** *Pancreas*, 2013. 42(7): p. 1157-63.
107. Xavier AC, Armeson KE, Hill EG, and Costa LJ, **Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.** *Cancer*, 2013. 119(18): p. 3385-92.
108. Xiao Q, Arem H, Moore SC, Hollenbeck AR, and Matthews CE, **A large prospective investigation of sleep duration, weight change, and obesity in the NIH-AARP Diet and Health Study cohort.** *Am J Epidemiol*, 2013. 178(11): p. 1600-10.
109. Xiao Q, Yang HP, Wentzensen N, Hollenbeck A, and Matthews CE, **Physical activity in different periods of life, sedentary behavior, and the risk of ovarian cancer in the NIH-AARP diet and health study.** *Cancer Epidemiol Biomarkers Prev*, 2013. 22(11): p. 2000-8.

110. Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, Hollenbeck A, Park Y, Sherman ME, and Brinton LA, **Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.** *Am J Epidemiol*, 2013. 177(2): p. 142-51.
111. Yasmeen S, Chlebowski RT, Xing G, Morris CR, and Romano PS, **Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005.** *Cancer Med*, 2013. 2(4): p. 526-36.
112. Yendamuri S, Huang M, Malhotra U, Warren GW, Bogner PN, Nwogu CE, Groman A, and Demmy TL, **Prognostic implications of signet ring cell histology in esophageal adenocarcinoma.** *Cancer*, 2013. 119(17): p. 3156-61.